The US FDA’s proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing
Contents
Appearance
Names | |
---|---|
Preferred IUPAC name
N,N,N-Trimethyl-3-({[(propan-2-yl)oxy](methylphosphonoyl)}oxy)-5-{3-[3-(trimethylazaniumyl)phenoxy]propoxy}anilinium bis(tetraphenylboranuide) | |
Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C73H81B2N2O5P | |
Molar mass | 1119.05 g·mol−1 |
Appearance | Solid |
Melting point | 97–100 °C (207–212 °F; 370–373 K) |
Insoluble | |
Solubility | Soluble in acetone |
Hazards | |
Occupational safety and health (OHS/OSH): | |
Main hazards
|
Extremely toxic |
Lethal dose or concentration (LD, LC): | |
LD50 (median dose)
|
74 μg/kg (Rats, IV) 15 μg/kg (Rabbits, IV) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
EA-2054 is an extremely toxic organophosphate nerve agent. It is an extremely potent acetylcholinesterase inhibitor that is resistant to atropine and oxime treatment.[1]